CHAI TRUST CO LLC
Long book
$1.18B
Q1 2026
Positions
11
Top-10 weight
99%
concentration
Last quarter
+20.5%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsCHAI TRUST CO LLC is an institutional manager, specialised in healthcare (90% of the long book), running a $1.18B US long book across 11 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: ARDENT HEALTH INC, VANGUARD TOTAL STOCK MKT ETF, INVESCO S&P 500 EQUAL WEIGHT, VANGUARD FTSE DEVELOPED ETF, VANGUARD S&P 500 ETF.
Over the last 9 quarters its long book ran on average 6.1pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. Signal value of individual moves is limited — treat changes as weak evidence.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+0.4%
Q2 2024
+6.7%
Q3 2024
-5.9%
Q4 2024
-13.5%
Q1 2025
+1.3%
Q2 2025
-0.0%
Q3 2025
-21.8%
Q4 2025
-2.4%
Q1 2026
+20.5%
Sector allocation
Healthcare 100%
Long book by quarter
What does CHAI TRUST own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ARDT ARDENT HEALTH INC | Healthcare | 77.2M | $661.2M | 56.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 12 | $1.18B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 12 | $1.16B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 12 | $1.51B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 13 | $1.63B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 14 | $1.61B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 14 | $1.93B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 14 | $2.11B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 12 | $649.2M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | Apr 30, 2024 | 16 | $922.3M | canonical | SEC ↗ |